Last updated: December 12, 2023
Sponsor: United Therapeutics
Overall Status: Completed
Phase
3
Condition
Williams Syndrome
Vascular Diseases
Circulation Disorders
Treatment
treprostinil diethanolamine
UT-15C SR
Clinical Study ID
NCT01934582
TDE-PH-309
TDE-PH-304
Ages 12-75 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Only subjects who are eligible for and have entered into Protocol TDE-PH-304 mayparticipate in this substudy.
Exclusion
Exclusion Criteria:
- The subject must voluntarily give informed consent to participate in the substudy.
- No dose changes to study drug are made within 5 days of the pharmacokinetic (PK)substudy visits.
- No additions or deletions to concurrent medications are made within 7 days of thepharmacokinetic substudy visit. Note: changes to diuretics and/or anticoagulants arepermitted.
- The preceding evening dose of study drug should have been taken 9 to 13 hours prior tothe BID dose and 6-10 hours prior to the TID morning dose of study drug to ensure atrough level of study drug for PK sampling.
- Subject dosing of study drug on the day of PK sampling must be observed in the clinicby study personnel.
- Subject has not experienced a significant loss of blood (> 450 mL) within the last 6weeks of the pharmacokinetic substudy visit.
- The subject must not be receiving any CYP 2C8 inducers or inhibitors
Study Design
Total Participants: 13
Treatment Group(s): 2
Primary Treatment: treprostinil diethanolamine
Phase: 3
Study Start date:
August 01, 2013
Estimated Completion Date:
November 30, 2013
Study Description
Connect with a study center
University of Rochester Medical Center
Rochester, New York 14623
United StatesSite Not Available
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.